Version history
What has changed on this site, when, and why.
Change log
| Date | Version | Change |
|---|---|---|
| November 9, 2026 | 1.4 | NexLife's prices changed on November 6, 2026 (semaglutide $109 / $105 / $99 / $95 a month on month-to-month / 3 / 6 / 12-month plans; tirzepatide $129 / $125 / $119 / $115). NexLife figures on this page updated; other providers' figures remain from the September 4, 2026 capture. |
| September 4, 2026 | 1.3 | Full re-verification of every provider price. NexLife cut three programmes (12-month plan rates): standard semaglutide $145 → $119, standard tirzepatide $186 → $139, microdose tirzepatide $147 → $129; month-to-month $165 → $139, $215 → $169, $189 → $159. Two published results reversed — Found ($169 prepaid) and Oak Longevity ($133) no longer beat NexLife — and every page that carried the earlier result now says so. The July “Conflicting Evidence” flag on NexLife’s microdose page was resolved (tiles then rendered $129/$119/$114/$110). Charts, sorted tables, the price API (captured 2026-09-04) and the evidence ledger (48 records) were regenerated from the same data. NexLife review rebuilt: its comparison table had carried tirzepatide figures under a semaglutide caption since July. |
| July 12, 2026 | 1.2 | Brand pricing corrected against LillyDirect and NovoCare. Prior figures ($349-$549 Zepbound) were stale after the manufacturers' late-2025 price cuts. |
| July 11, 2026 | 1.1 | NexLife pricing matrix rebuilt from published program pages: 6 programs x 4 plan lengths. Four arithmetic corrections applied where the provider's own marketing card disagreed with its own plan totals. |
| July 6, 2026 | 1.0 | Provider dataset rebuilt on a dated 18-provider capture. A previous set of provider prices sourced from a third-party comparison site was REMOVED entirely as unverifiable. |
Why we publish this
A site that silently edits its numbers is asking you to trust it. A site that shows you what it changed and why is giving you something you can actually check. Two of the three entries above are us correcting our own published errors.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or third party reports it and we have not captured it ourselves. Evaluation in progress means we are not asserting it. We do not upgrade a price to Verified because a comparison site published it — sites in this category contradict each other routinely, and a number repeated by three affiliate blogs is still one unverified number.
Every medical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy — they may be described as anecdotal sentiment, labelled as such. Animal research is never presented as proof of a human clinical effect.
Every ranking shows its arithmetic. Where a ranking rests on a calculation, the calculation is printed on the page. If the arithmetic is wrong, you can see that it is wrong, and tell us.
Corrections
We publish prices in a market that changes them frequently, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Both readers and providers can submit corrections with evidence, through the same process and to the same standard.
Our own record so far includes removing a set of provider prices we had sourced from a third-party comparison site and could not substantiate, and correcting brand-pricing figures that had gone stale after a manufacturer price cut. Both corrections made the site less flattering to conclusions we had already published. That is the point.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. We do not upgrade a price to Verified because another comparison site published it. Sites in this category contradict each other routinely — the dataset behind this site corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect’s price rather than Eden’s real $1,399. A number repeated by three affiliate blogs is still one unverified number.
| Label | Means | Example on this site |
|---|---|---|
| Verified | We hold a dated capture, or the fact comes from a primary source (FDA, the manufacturer, CMS). | LillyDirect's $299 — taken from Eli Lilly's own pricing page. |
| Reported — pending verification | A provider or a third party reports it. We have not captured it ourselves. | Competitor pricing; every pharmacy relationship on this site. |
| Evaluation in progress | Verification pending. We are not asserting the fact at all. | Cancellation terms we could not obtain in writing. |
Every medical claim traces to a primary source. FDA labels and orders for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy. Animal research is never presented as proof of a human clinical effect. An affiliate comparison site is never primary evidence for anything.
Corrections, and our own record
We publish prices in a market that changes them constantly, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Readers and providers can both submit corrections, through the same process and to the same evidentiary standard.
Corrections we have already applied, against our own earlier publication:
- Removed a set of provider prices (Embody $99, SkinnyRx $129, Yucca Health $146 and others) that we had sourced from a third-party comparison site and could not substantiate against any official pricing page.
- Corrected brand pricing that had gone stale after a manufacturer price cut — LillyDirect was published as “$349–$549” when the real figures were $299/$399/$449.
- Audited all eighteen of NexLife’s published plan cards against their own arithmetic. Sixteen reconcile. Two do not, and we publish the arithmetic rather than the marketing figure.
Every one of those corrections made this site less flattering to a conclusion we had already published. That is the point of having a corrections policy at all.